Increasing trend of utilising active surveillance for Gleason Score 7 (3+4) prostate cancer

被引：2
|
作者：
Bernardino, Rui [1 ,4 ,6 ]
Sayyid, Rashid K. [1 ]
Leao, Ricardo [5 ]
Zlotta, Alexandre R. [1 ]
van Der Kwast, Theodorus [2 ]
Klotz, Laurence [3 ]
Fleshner, Neil E. [1 ]
机构：
[1] Univ Toronto, Div Urol, Dept Surg Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON, Canada
[4] Univ NOVA Lisboa, Fac Ciencias Med, NOVA Med Sch, Computat & Expt Biol Grp, Lisbon, Portugal
[5] Hosp Cuf, Coimbra, Portugal
[6] Univ Toronto, Princess Margaret Canc Ctr, 700 Univ Ave, Toronto, ON M5G 1Z5, Canada
来源：
BJU INTERNATIONAL | 2023年 / 132卷 / 06期
关键词：
D O I：
10.1111/bju.16162
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：638 / 640
页数：3
相关论文
共 50 条
  • [31] Gleason Score 3+4=7 Prostate Cancer with Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Often Associated with Low Risk Tumor
    Deng, F-M
    Huang, C. C.
    Kong, M.
    Xu, X.
    Zhou, M.
    Melamed, J.
    MODERN PATHOLOGY, 2014, 27 : 224A - 224A
  • [32] Gleason Score 3+4=7 Prostate Cancer with Minimal Quantity of Gleason Pattern 4 on Needle Biopsy Is Often Associated with Low Risk Tumor
    Deng, F-M
    Huang, C. C.
    Kong, M.
    Xu, W.
    Zhou, M.
    Melamed, J.
    LABORATORY INVESTIGATION, 2014, 94 : 224A - 224A
  • [33] CAN WE CONSIDER PATIENTS WITH LIMITED BIOPSY GLEASON SCORE 3+4 ELIGIBLE FOR ACTIVE SURVEILLANCE?
    Gandaglia, Giorgio
    Suardi, Nazareno
    Abdollah, Firas
    Capitanio, Umberto
    Moschini, Marco
    Zaffuto, Emanuele
    Bertini, Roberto
    Villa, Luca
    Di Girolamo, Valerio
    Freschi, Massimo
    Scattoni, Vincenzo
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Briganti, Alberto
    JOURNAL OF UROLOGY, 2014, 191 (04): : E814 - E814
  • [34] 3+4=6? Implications of the stratification of localised Gleason 7 prostate cancer by number and percentage of positive biopsy cores in selecting patients for active surveillance
    Ruiz-Cerda, J. L.
    Lorenzo Soriano, L.
    Ramos-Soler, D.
    Marzullo-Zucchet, L.
    Loras Monfort, A.
    Boronat Tormo, F.
    ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (02): : 103 - 113
  • [35] Molecular Prognostic Testing on Gleason 3+4 Prostate Cancer
    Lin, Kirk
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 922 - 923
  • [36] Outcomes of Gleason score 3+4=7 prostate cancer with minimal amounts (<6%) vs ≥6% of Gleason pattern 4 tissue in needle biopsy specimens
    Kir, Gozde
    Seneldir, Hatice
    Gumus, Eyup
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2016, 20 : 48 - 51
  • [37] Molecular Prognostic Testing on Gleason 3+4 Prostate Cancer
    Lin, Kirk
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 922 - 923
  • [38] Gleason Score 3+4=7 Prostate Cancer with Minimal Pattern 4 Identified in Prostate Needle Biopsy Barely has Worse Pathological Outcomes
    Serrano, Antonio
    Melamed, Jonathan
    Ren, Qinghu
    Huang, Hongying
    Park, Kyung
    Flaifel, Abdallah
    Deng, Fangming
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 969 - 971
  • [39] Gleason Score 3+4=7 Prostate Cancer with Minimal Pattern 4 Identified in Prostate Needle Biopsy Barely has Worse Pathological Outcomes
    Serrano, Antonio
    Melamed, Jonathan
    Ren, Qinghu
    Huang, Hongying
    Park, Kyung
    Flaifel, Abdallah
    Deng, Fangming
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 969 - 971
  • [40] INCREASING ELIGIBILITY FOR PROSTATE CANCER ACTIVE SURVEILLANCE: THE VALUE OF MULTIPARAMETRIC MRI FOR THE PREDICTION OF PATHOLOGICAL DOWNGRADING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH BIOPSY-PROVEN GLEASON 3+4 PROSTATE CANCER
    Gondo, Tatsuo
    Hricak, Hedvig
    Sala, Evis
    Zheng, Junting
    Moskowitz, Chaya S.
    Bernstein, Melanie
    Scardino, Peter T.
    Eastham, James A.
    Vargas, Hebert Alberto
    JOURNAL OF UROLOGY, 2014, 191 (04): : E55 - E55
12345